A new drug class that is currently being investigated is the OX40 inhibitor, which targets OX40 receptors and ligands. OX40 inhibitors may be promising as AD treatments, as key opinion leaders ...

“The marked and durable clinical and pharmacodynamic activities observed in Cohort 2 after a 4-week treatment, combined with a well-tolerated profile, suggest that blocking the OX40-OX40L ...

ORLANDO -- A novel therapy for atopic dermatitis (AD) led to at least 75% improvement in a third of patients after 6 months, ...

Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic ...

Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morning with the news that the highest dose of the anti-OX40-ligand monoclonal antibody missed the main goal of a phase ...

The firm's decision follows Astria's announcement of the initiation of a Phase 1a study for STAR-0310, a monoclonal antibody and OX40 antagonist, aimed at treating atopic dermatitis and ...

KY1005 – now renamed amlitelimab – is one of a handful of new drugs targeting OX40 ligand, an immune system regulator delivered by intravenous infusion once every 28 days. It is also being ...

For these reasons, molecules targeting direct activation of immune cells, including antibodies to receptors such as OX40, CD40 and others on immune cells with a stimulatory mechanism of action ...